Topical Janus kinase inhibitors: A review of applications in dermatology
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference44 articles.
1. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases;Schwartz;Nat Rev Rheumatol,2016
2. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects;Banerjee;Drugs,2017
3. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases;Roskoski;Pharmacol Res,2016
4. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial;Al-Ali;Haematologica,2016
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A meta-analysis of therapeutic trials of topical ruxolitinib cream for the treatment of vitiligo: therapeutic efficacy, safety, and implications for therapeutic practice;Archives of Dermatological Research;2024-08-12
2. An overview of Skp2: a promising new therapeutic target of psoriasis;Expert Opinion on Therapeutic Targets;2024-08-02
3. Efficacy of Topical Tofacitinib 2% Gel in Chronic Hand Eczema – A Case Series;Indian Dermatology Online Journal;2024-06-03
4. A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris;International Journal of Innovative Science and Research Technology (IJISRT);2024-05-28
5. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition;Journal of Clinical Medicine;2024-05-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3